Oral, fixed dose combination of 300 mg of netupitant, a highly selective NK1 receptor antagonist, and 0.5 mg of palonosetron a distinct 5-HT3 receptor antagonist, for the prevention of chemotherapy induced nausea and vomiting (CINV).
A single pill alternative to multi agent antiemetic regimens for CINV.
This drug combination is superior to oral palonosetron for prevention of CINV in highly emetogenic chemotherapy.
Efficacious and well tolerated.
Views: 3